TGFB1 and neoplasm: Given its specific replication in tumor cells and TME, but not in healthy tissue, VSV could therefore act as a local inhibitor of TGF-β, and thereby therapeutically modulate fibrosis, without the drawbacks of systemic alteration of TGF-β signaling.